NEW YORK (GenomeWeb) – Investment bank Canaccord Genuity today upgraded shares of Quest Diagnostics and Laboratory Corporation of America to Buy ratings on expectations that visits to primary care physicians and laboratory testing will increase in 2015 over 2014 levels. 

Analyst Mark Massaro upgraded the ratings for both companies from prior Hold ratings. He also increased his price target on Quest to $82 from an earlier $63 target, and the price target on LabCorp to $145 from $100. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.